This Week in Orthopedics — Sep 17, 2026

Welcome to This Week in Orthopedics. This week we're covering 10 notable papers spanning bone and joint infection, perioperative pathways and consensus statements, and a hard look at technology and implant performance, plus a cluster of shoulder and knee papers. Let's dive in.

We start with infection, and the headline paper of the week comes from the New England Journal of Medicine. McNally and colleagues report SOLARIO, a multicentre, open-label noninferiority trial in 500 adults who had surgery for orthopedic infection with implantation of a local antibiotic carrier at the time of debridement [1]. Patients were randomised to systemic antibiotics for four weeks or longer, or for seven days or fewer. Definite treatment failure at twelve months, adjudicated by a blinded endpoint committee, occurred in about 14 percent of the long-course group and about 11 percent of the short-course group, comfortably within the prespecified noninferiority margin, and sensitivity analyses in the per-protocol population were consistent. The safety signal is where this becomes genuinely practice-changing. By six weeks after surgery, treatment-related symptoms had occurred in close to half of the patients on the long course, compared with roughly one in six on the short course — an absolute reduction of about 28 percentage points. The caveat matters: every patient received a local antibiotic carrier, so this is not a licence to shorten systemic therapy when you have not delivered antibiotics to the site.

That theme of questioning inherited infection dogma continues in the Journal of Bone and Joint Surgery, where Ascione and colleagues take on the two-week antibiotic holiday before reimplantation in two-stage exchange for periprosthetic joint infection [2]. Their argument is that the metrics we use to time reimplantation — serum inflammatory markers, synovial markers, culture results — have poor predictive value and are often discordant, and that the rationale for stopping antibiotics so that persistent infection can resurface has never been supported by outcome data. They find no clear evidence that an antibiotic holiday improves results, while continuous therapy shortens overall treatment duration and may deliver higher cure rates, particularly in immunocompromised patients. Read alongside SOLARIO, the direction of travel is clear: we are moving away from ritualised antibiotic scheduling toward decisions driven by source control and local delivery. And on local delivery, also in the Journal of Bone and Joint Surgery, Hammad and colleagues offer a very practical in vitro study of sixty polymethylmethacrylate discs loaded with four grams of vancomycin [3]. Cement brand, viscosity and — strikingly — the order in which you mix all changed elution substantially. Monomer-first mixing of medium-viscosity Palacos produced the greatest cumulative release over 28 days, more than double that of monomer-first Simplex, while polymer-first Simplex gave the biggest burst in the first hour. Porosity and bactericidal activity were unaffected. If you make high-dose spacers, the scrub-nurse-level detail of mixing sequence is now a variable you should be specifying deliberately.

Our second theme is perioperative pathways, and here we have two consensus documents with very different geography. In Knee Surgery, Sports Traumatology, Arthroscopy, Totlis and colleagues report a formal consensus on fast-track hip and knee arthroplasty, developed by 106 experts across steering, rating and peer-review groups on behalf of ESSKA, the European Knee Associates, the European Hip Society and the Arthroplasty Society of Australia [4]. Thirty-seven questions generated 63 statements covering preoperative, intraoperative and postoperative care, and it is worth noting that a clear majority of those statements — 39 of 63 — rest on high or moderate-level evidence rather than expert opinion alone. Mean agreement was high throughout. This is a pragmatic framework for reducing morbidity, optimising analgesia, shortening stay and enabling safe early mobilisation, and the authors are explicit that it supplements rather than replaces clinical judgement. Complementing that, in the Journal of Bone and Joint Surgery, Mao and colleagues present the WAIT-Free consensus, which tackles a genuine global equity problem [5]. Immediate weight-bearing as tolerated after hip fracture surgery is routine in North America and Europe but is not standard practice across regions representing more than half the world's population. Thirty-one experts from fifteen countries used a three-round Delphi process to produce thirteen recommendations built around shared decision-making, stratification by pre-fracture mobility, structured fall prevention and multidisciplinary optimisation, and stability-based triage after fixation versus arthroplasty, with a supportive-factor checklist for phased implementation in resource-constrained settings. The clinical message for everyone, wherever you practise, is that patients who were independently ambulatory before the fracture should be prioritised for immediate weight-bearing.

Our third theme is a sober one: technology and implant performance under scrutiny. Fraval and colleagues, in the Journal of Bone and Joint Surgery, review the contemporary evidence on robotic-assisted joint replacement [6]. Their conclusion is unambiguous. Robotics reliably improves the precision and reproducibility of component positioning, but systematic reviews, meta-analyses, randomised trials and national registry data have not shown consistent improvements in patient-reported outcomes, complication rates or implant survivorship. They flag statistical fragility, heterogeneity between platforms, and a widening gap between the evidence and public enthusiasm — and they argue for an evidence-based framework for innovation in which adoption follows demonstrated patient benefit, not technical elegance. The companion cautionary tale, also in the Journal of Bone and Joint Surgery, comes from Prentice and colleagues, who used a United States health-care system registry of nearly fourteen thousand shoulder arthroplasties to examine revision risk after the 2024 Exactech Equinoxe recall for non-conforming packaging [7]. For anatomic total shoulder arthroplasty, Equinoxe devices carried close to double the adjusted risk of all-cause revision compared with other implants, and the signal persisted when analysis was restricted to devices packaged in the non-conforming bags. Importantly, no difference was seen in elective reverse shoulder arthroplasty, and the fracture reverse cohort was too small to draw conclusions. Practically, if you have a patient with a previously implanted Equinoxe anatomic shoulder, this is a cohort worth watching more closely.

Finally, three papers on shoulder and knee management. In Arthroscopy, Hurley and colleagues deliver the third part of an international rotator cuff consensus, with 97 surgeons from fifteen countries generating 47 statements on reverse arthroplasty, revision surgery and rehabilitation [8]. There was consensus that reverse shoulder arthroplasty is indicated for irreparable tears, pseudoparalysis, or failed prior repair with pain and dysfunction, and contraindicated with inadequate deltoid or axillary nerve function or active infection. For return to play, the panel rejected any universal timeline, favouring clearance based on strength, motion, proprioception, pain resolution and psychological readiness. Notably, three statements reached no consensus at all, and the panel could not agree on an ideal follow-up or imaging surveillance protocol — an honest admission of where the evidence runs out. Also in Arthroscopy, Lee and colleagues report a retrospective cohort of 136 patients undergoing arthroscopic Bankart repair for recurrent anterior instability without significant glenoid bone loss [9]. Placing the most inferior anchor at the 6 o'clock position was associated with recurrence in about one in ten patients, compared with roughly a quarter of patients in the non-6-o'clock group, with better instability, Rowe and UCLA scores and no loss of range of motion. The caution is that rates of achieving the minimal clinically important difference did not differ between groups, and this is Level III retrospective data. And rounding out the week, Zhong and colleagues in Arthroscopy pooled 21 randomised trials and 1,790 patients comparing platelet-rich plasma with hyaluronic acid for knee osteoarthritis [10]. At three and six months there was no significant advantage on visual analogue pain scores; by twelve months platelet-rich plasma was significantly better for pain and favoured across all time points on WOMAC, but there were no differences on the Knee Injury and Osteoarthritis Outcome Score or the International Knee Documentation Committee score. The effects are small, heterogeneity and risk of bias were substantial, and follow-up stops at twelve months — so this supports platelet-rich plasma modestly over hyaluronic acid, not enthusiastically.

If you only have time for one paper this week, make it SOLARIO in the New England Journal of Medicine [1]. It is a properly powered randomised trial that lets you cut systemic antibiotics from weeks to a single week in appropriately managed orthopedic infection, with markedly fewer treatment-related symptoms — and that changes prescribing on Monday.

Here are the key takeaways from this week in Orthopedics. First, when local antibiotics are implanted at the time of surgery, seven days or less of systemic therapy is noninferior to four weeks or more, with far fewer side effects. Second, the two-week antibiotic holiday before reimplantation has no supporting outcome evidence, and continuous therapy may serve immunocompromised patients better. Third, if you make high-dose vancomycin spacers, cement brand, viscosity and mixing sequence measurably change how much drug you deliver. Fourth, robotics improves component positioning but has not yet improved outcomes or survivorship, and the Equinoxe anatomic shoulder registry signal is a reminder that new hardware needs surveillance, not just enthusiasm. And fifth, two new consensus documents give you a usable fast-track arthroplasty framework and a roadmap for immediate weight-bearing after hip fracture in settings where that is still not routine.

That's your roundup for This Week in Orthopedics. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.